| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 25 | 2025 | 866 | 2.700 |
Why?
|
| Xenograft Model Antitumor Assays | 40 | 2026 | 934 | 1.910 |
Why?
|
| Protein Kinase Inhibitors | 20 | 2026 | 981 | 1.830 |
Why?
|
| Antineoplastic Agents | 25 | 2020 | 2214 | 1.320 |
Why?
|
| Triple Negative Breast Neoplasms | 7 | 2024 | 218 | 1.320 |
Why?
|
| Azepines | 5 | 2024 | 105 | 1.280 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2025 | 293 | 1.250 |
Why?
|
| Cell Line, Tumor | 41 | 2026 | 3542 | 1.180 |
Why?
|
| Pancreatic Neoplasms | 9 | 2025 | 928 | 1.160 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2024 | 218 | 1.160 |
Why?
|
| Pyrimidines | 9 | 2020 | 530 | 1.070 |
Why?
|
| Mice, Nude | 25 | 2024 | 679 | 1.070 |
Why?
|
| Pyrazines | 6 | 2018 | 94 | 0.940 |
Why?
|
| Cell Proliferation | 23 | 2026 | 2507 | 0.920 |
Why?
|
| Apoptosis | 23 | 2026 | 2440 | 0.770 |
Why?
|
| Fluorouracil | 1 | 2022 | 231 | 0.690 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2026 | 72 | 0.630 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2025 | 1963 | 0.610 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2018 | 624 | 0.600 |
Why?
|
| Benzimidazoles | 6 | 2024 | 189 | 0.580 |
Why?
|
| Aurora Kinase A | 4 | 2020 | 61 | 0.580 |
Why?
|
| Camptothecin | 5 | 2022 | 138 | 0.580 |
Why?
|
| Imidazoles | 4 | 2018 | 247 | 0.580 |
Why?
|
| Mice | 45 | 2026 | 18329 | 0.540 |
Why?
|
| Tumor Microenvironment | 6 | 2023 | 734 | 0.540 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2024 | 881 | 0.520 |
Why?
|
| Drug Synergism | 4 | 2014 | 354 | 0.510 |
Why?
|
| Adrenal Cortex Neoplasms | 3 | 2026 | 70 | 0.490 |
Why?
|
| Deoxycytidine | 4 | 2024 | 220 | 0.480 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 630 | 0.450 |
Why?
|
| Animals | 50 | 2026 | 38030 | 0.450 |
Why?
|
| Cell Cycle Checkpoints | 3 | 2019 | 97 | 0.450 |
Why?
|
| Hydroxamic Acids | 3 | 2011 | 94 | 0.450 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2026 | 534 | 0.450 |
Why?
|
| Neoplasms | 9 | 2022 | 2906 | 0.440 |
Why?
|
| Wnt Signaling Pathway | 5 | 2024 | 211 | 0.440 |
Why?
|
| Melanoma | 5 | 2024 | 759 | 0.440 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2013 | 64 | 0.430 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 4560 | 0.410 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2014 | 288 | 0.410 |
Why?
|
| Antimitotic Agents | 1 | 2013 | 8 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2024 | 1443 | 0.410 |
Why?
|
| Pyrazoles | 5 | 2018 | 517 | 0.400 |
Why?
|
| Molecular Targeted Therapy | 3 | 2024 | 439 | 0.390 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 4 | 2022 | 44 | 0.380 |
Why?
|
| Signal Transduction | 18 | 2024 | 5216 | 0.380 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2013 | 122 | 0.370 |
Why?
|
| Boronic Acids | 2 | 2011 | 36 | 0.370 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2018 | 454 | 0.360 |
Why?
|
| Quinoxalines | 4 | 2020 | 65 | 0.350 |
Why?
|
| Biomarkers, Tumor | 7 | 2025 | 1321 | 0.340 |
Why?
|
| Dasatinib | 2 | 2024 | 58 | 0.330 |
Why?
|
| Humans | 72 | 2026 | 145475 | 0.330 |
Why?
|
| Gene Expression Profiling | 8 | 2024 | 1767 | 0.330 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 257 | 0.320 |
Why?
|
| Drug Screening Assays, Antitumor | 5 | 2020 | 194 | 0.320 |
Why?
|
| Pyridines | 3 | 2022 | 609 | 0.310 |
Why?
|
| Heterografts | 3 | 2021 | 143 | 0.310 |
Why?
|
| Programmed Cell Death 1 Receptor | 3 | 2025 | 265 | 0.300 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 2020 | 27 | 0.300 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2018 | 382 | 0.280 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2025 | 992 | 0.270 |
Why?
|
| Ephrin-B2 | 2 | 2019 | 45 | 0.270 |
Why?
|
| Enzyme Inhibitors | 5 | 2020 | 820 | 0.260 |
Why?
|
| Cell Cycle | 7 | 2018 | 598 | 0.260 |
Why?
|
| Piperazines | 2 | 2020 | 375 | 0.260 |
Why?
|
| Quinazolines | 3 | 2015 | 266 | 0.250 |
Why?
|
| Female | 44 | 2026 | 78845 | 0.250 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 381 | 0.240 |
Why?
|
| Anilides | 2 | 2018 | 84 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2019 | 126 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 212 | 0.240 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2025 | 14 | 0.230 |
Why?
|
| CD47 Antigen | 1 | 2025 | 42 | 0.230 |
Why?
|
| Gene Dosage | 4 | 2015 | 145 | 0.230 |
Why?
|
| Mutation | 9 | 2018 | 4075 | 0.220 |
Why?
|
| Nephritis, Interstitial | 1 | 2025 | 11 | 0.220 |
Why?
|
| Immunoblotting | 6 | 2015 | 295 | 0.220 |
Why?
|
| Cyclosporine | 2 | 2018 | 256 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2020 | 153 | 0.220 |
Why?
|
| Gene Regulatory Networks | 2 | 2024 | 317 | 0.210 |
Why?
|
| Collagen Type I | 1 | 2025 | 143 | 0.210 |
Why?
|
| Organoids | 2 | 2024 | 145 | 0.210 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2018 | 223 | 0.210 |
Why?
|
| Pyrimidinones | 2 | 2015 | 125 | 0.210 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2025 | 179 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 6 | 2016 | 254 | 0.200 |
Why?
|
| RNA, Small Interfering | 2 | 2024 | 637 | 0.200 |
Why?
|
| Endogenous Retroviruses | 1 | 2024 | 37 | 0.200 |
Why?
|
| ras Proteins | 4 | 2013 | 150 | 0.200 |
Why?
|
| Bevacizumab | 1 | 2024 | 168 | 0.200 |
Why?
|
| Receptor, Notch1 | 2 | 2015 | 63 | 0.200 |
Why?
|
| Mucous Membrane | 1 | 2024 | 128 | 0.200 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 246 | 0.200 |
Why?
|
| Pyridones | 2 | 2015 | 209 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
|
| Collagen | 1 | 2025 | 457 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2024 | 257 | 0.190 |
Why?
|
| HCT116 Cells | 3 | 2018 | 76 | 0.180 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2022 | 69 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 198 | 0.180 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2023 | 166 | 0.180 |
Why?
|
| Immunotherapy | 3 | 2022 | 666 | 0.180 |
Why?
|
| Drug Design | 2 | 2013 | 175 | 0.180 |
Why?
|
| Cetuximab | 2 | 2025 | 111 | 0.170 |
Why?
|
| Doxorubicin | 1 | 2024 | 401 | 0.170 |
Why?
|
| beta Catenin | 2 | 2020 | 254 | 0.170 |
Why?
|
| Quinolines | 1 | 2022 | 190 | 0.170 |
Why?
|
| Gene Knockdown Techniques | 4 | 2020 | 333 | 0.170 |
Why?
|
| Momordica charantia | 1 | 2020 | 12 | 0.160 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 1480 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 20 | 0.160 |
Why?
|
| HT29 Cells | 2 | 2018 | 37 | 0.160 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 167 | 0.150 |
Why?
|
| Immune System | 1 | 2021 | 180 | 0.150 |
Why?
|
| eIF-2 Kinase | 1 | 2019 | 28 | 0.150 |
Why?
|
| src-Family Kinases | 2 | 2017 | 92 | 0.150 |
Why?
|
| Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2016 | 90 | 0.140 |
Why?
|
| DNA Helicases | 1 | 2020 | 136 | 0.140 |
Why?
|
| Plant Extracts | 1 | 2020 | 188 | 0.140 |
Why?
|
| Tumor Burden | 2 | 2018 | 325 | 0.140 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 29 | 0.140 |
Why?
|
| Coenzymes | 1 | 2018 | 19 | 0.140 |
Why?
|
| 4-Aminobenzoic Acid | 1 | 2018 | 8 | 0.140 |
Why?
|
| Thermodynamics | 1 | 2020 | 419 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 441 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2015 | 70 | 0.140 |
Why?
|
| Septins | 1 | 2018 | 43 | 0.130 |
Why?
|
| Adrenal Cortex | 1 | 2018 | 33 | 0.130 |
Why?
|
| Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 3 | 2020 | 506 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 41 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2018 | 238 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 86 | 0.120 |
Why?
|
| Kidney | 1 | 2025 | 1497 | 0.120 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 849 | 0.120 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cyclopentanes | 1 | 2016 | 17 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 886 | 0.120 |
Why?
|
| Transplantation, Heterologous | 4 | 2022 | 170 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 4 | 2025 | 1261 | 0.120 |
Why?
|
| Corynebacterium | 1 | 2017 | 49 | 0.120 |
Why?
|
| Corynebacterium Infections | 1 | 2017 | 42 | 0.120 |
Why?
|
| Tankyrases | 1 | 2016 | 13 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 105 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2018 | 317 | 0.120 |
Why?
|
| Capecitabine | 1 | 2015 | 56 | 0.120 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2013 | 78 | 0.120 |
Why?
|
| Autophagy | 1 | 2018 | 291 | 0.120 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2015 | 31 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2016 | 153 | 0.110 |
Why?
|
| Genes, ras | 2 | 2018 | 96 | 0.110 |
Why?
|
| Cell Survival | 3 | 2019 | 1100 | 0.110 |
Why?
|
| Diphenylamine | 1 | 2014 | 7 | 0.110 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 925 | 0.110 |
Why?
|
| Middle Aged | 15 | 2025 | 36215 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2024 | 2597 | 0.110 |
Why?
|
| Aged | 12 | 2025 | 26153 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2015 | 184 | 0.110 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 176 | 0.100 |
Why?
|
| Piperidines | 1 | 2015 | 222 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 76 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2015 | 312 | 0.100 |
Why?
|
| Benzamides | 1 | 2014 | 226 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2016 | 847 | 0.100 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 258 | 0.100 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 93 | 0.100 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2013 | 31 | 0.100 |
Why?
|
| Valine | 1 | 2013 | 83 | 0.100 |
Why?
|
| Neutrophils | 4 | 2019 | 1124 | 0.090 |
Why?
|
| Bortezomib | 2 | 2011 | 54 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 90 | 0.090 |
Why?
|
| Mitosis | 1 | 2013 | 193 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 321 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2013 | 178 | 0.090 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 149 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 641 | 0.090 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2012 | 99 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 561 | 0.090 |
Why?
|
| Sirolimus | 1 | 2013 | 280 | 0.080 |
Why?
|
| Proteasome Inhibitors | 1 | 2011 | 41 | 0.080 |
Why?
|
| Adult | 13 | 2025 | 40777 | 0.080 |
Why?
|
| Computational Biology | 1 | 2015 | 669 | 0.080 |
Why?
|
| DNA Damage | 2 | 2026 | 437 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 102 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2018 | 440 | 0.080 |
Why?
|
| Carcinogenesis | 2 | 2024 | 228 | 0.080 |
Why?
|
| Benzodioxoles | 1 | 2012 | 161 | 0.080 |
Why?
|
| Phosphorylation | 4 | 2019 | 1707 | 0.080 |
Why?
|
| Mice, Inbred NOD | 2 | 2022 | 613 | 0.080 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 688 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 740 | 0.080 |
Why?
|
| Male | 16 | 2025 | 72843 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 74 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2009 | 73 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 108 | 0.070 |
Why?
|
| Cell Movement | 2 | 2011 | 959 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 2382 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 838 | 0.070 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 343 | 0.070 |
Why?
|
| Farnesyltranstransferase | 1 | 2007 | 21 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 372 | 0.060 |
Why?
|
| Prognosis | 4 | 2019 | 4316 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 749 | 0.060 |
Why?
|
| Protein Conformation | 2 | 2020 | 938 | 0.060 |
Why?
|
| Gene Expression | 2 | 2019 | 1476 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2024 | 157 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2024 | 1454 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 2 | 2020 | 210 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2010 | 1111 | 0.060 |
Why?
|
| Algorithms | 3 | 2024 | 1845 | 0.060 |
Why?
|
| Microsatellite Instability | 1 | 2025 | 55 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2010 | 3413 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 2 | 2018 | 286 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2025 | 40 | 0.050 |
Why?
|
| Disease Progression | 2 | 2025 | 2864 | 0.050 |
Why?
|
| Quinolones | 1 | 2007 | 203 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2025 | 105 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2020 | 1598 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2025 | 333 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 563 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2019 | 39 | 0.050 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2024 | 191 | 0.050 |
Why?
|
| HMGB1 Protein | 1 | 2003 | 51 | 0.050 |
Why?
|
| Triazoles | 1 | 2024 | 187 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 666 | 0.050 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2002 | 28 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.050 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2002 | 34 | 0.050 |
Why?
|
| Neuroimmunomodulation | 1 | 2002 | 67 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 627 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2002 | 92 | 0.040 |
Why?
|
| Histone Deacetylase 1 | 1 | 2022 | 23 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2003 | 294 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2023 | 144 | 0.040 |
Why?
|
| Aurora Kinases | 2 | 2012 | 28 | 0.040 |
Why?
|
| Histones | 2 | 2022 | 666 | 0.040 |
Why?
|
| Endotoxemia | 1 | 2002 | 86 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 2378 | 0.040 |
Why?
|
| Caspase 3 | 2 | 2013 | 242 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2024 | 11772 | 0.040 |
Why?
|
| Acetylation | 1 | 2022 | 259 | 0.040 |
Why?
|
| Chimerism | 1 | 2021 | 35 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2019 | 1162 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2023 | 385 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 252 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 562 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2021 | 77 | 0.040 |
Why?
|
| Campylobacter jejuni | 1 | 2000 | 16 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2012 | 500 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2021 | 78 | 0.040 |
Why?
|
| Catalase | 1 | 2000 | 134 | 0.040 |
Why?
|
| TCF Transcription Factors | 1 | 2020 | 19 | 0.040 |
Why?
|
| Histone Deacetylases | 1 | 2022 | 207 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 369 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 83 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 106 | 0.040 |
Why?
|
| Indolizines | 1 | 2019 | 13 | 0.040 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 138 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2013 | 28 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2020 | 111 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2013 | 70 | 0.040 |
Why?
|
| Genomics | 1 | 2024 | 825 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2020 | 486 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1999 | 272 | 0.040 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
|
| Flavin-Adenine Dinucleotide | 1 | 2018 | 15 | 0.030 |
Why?
|
| NADP | 1 | 2018 | 52 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2020 | 219 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 176 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2019 | 204 | 0.030 |
Why?
|
| Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
|
| Nausea | 1 | 2018 | 112 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 1999 | 195 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1044 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 969 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2018 | 331 | 0.030 |
Why?
|
| Adenine | 1 | 2020 | 339 | 0.030 |
Why?
|
| Breast | 1 | 2018 | 156 | 0.030 |
Why?
|
| RNA | 1 | 2024 | 910 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2018 | 234 | 0.030 |
Why?
|
| Diarrhea | 1 | 2018 | 193 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2002 | 822 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2020 | 1368 | 0.030 |
Why?
|
| Autistic Disorder | 1 | 1999 | 219 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 767 | 0.030 |
Why?
|
| Axin Protein | 1 | 2016 | 18 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2016 | 118 | 0.030 |
Why?
|
| Hypertension | 2 | 2018 | 1273 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 397 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 442 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2020 | 2803 | 0.030 |
Why?
|
| Fatigue | 1 | 2018 | 364 | 0.030 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 409 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 866 | 0.030 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.030 |
Why?
|
| Jagged-1 Protein | 1 | 2015 | 22 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 5983 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 66 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2015 | 18 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 1310 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1716 | 0.030 |
Why?
|
| NF-kappa B | 3 | 2003 | 666 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 699 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1082 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2015 | 238 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 221 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2013 | 22 | 0.030 |
Why?
|
| Butadienes | 1 | 2013 | 33 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3124 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2015 | 376 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 48 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1374 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 34 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 919 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 3155 | 0.020 |
Why?
|
| Everolimus | 1 | 2013 | 112 | 0.020 |
Why?
|
| Random Allocation | 1 | 2013 | 365 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 207 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 2 | 2003 | 146 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 148 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2003 | 264 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1471 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1567 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2013 | 245 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2003 | 762 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2012 | 325 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2012 | 165 | 0.020 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 15 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2012 | 226 | 0.020 |
Why?
|
| Population Groups | 1 | 2010 | 56 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2010 | 73 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 154 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2010 | 117 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 665 | 0.020 |
Why?
|
| Capillary Permeability | 1 | 2010 | 132 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2010 | 249 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 345 | 0.020 |
Why?
|
| Metabolome | 1 | 2013 | 388 | 0.020 |
Why?
|
| Australia | 1 | 2010 | 288 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2010 | 396 | 0.020 |
Why?
|
| Transcriptome | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1164 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1505 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 4295 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 977 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 848 | 0.020 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 17 | 0.020 |
Why?
|
| Verapamil | 1 | 2007 | 37 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 1190 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2009 | 1179 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2011 | 583 | 0.020 |
Why?
|
| Clone Cells | 1 | 2007 | 263 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 2028 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2007 | 166 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 686 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3904 | 0.010 |
Why?
|
| Indoles | 1 | 2009 | 507 | 0.010 |
Why?
|
| Family | 1 | 2010 | 682 | 0.010 |
Why?
|
| Metabolomics | 1 | 2011 | 732 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 6013 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 776 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 595 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 2003 | 26 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2003 | 10 | 0.010 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 5 | 0.010 |
Why?
|
| Phentolamine | 1 | 2002 | 19 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2002 | 26 | 0.010 |
Why?
|
| Brimonidine Tartrate | 1 | 2002 | 10 | 0.010 |
Why?
|
| Propranolol | 1 | 2002 | 44 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2002 | 74 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 302 | 0.010 |
Why?
|
| Chemokines | 1 | 2003 | 217 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 135 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 22530 | 0.010 |
Why?
|
| Peroxidase | 1 | 2002 | 168 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 424 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 125 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 239 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 14219 | 0.010 |
Why?
|
| Respiratory Burst | 1 | 2000 | 19 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 2000 | 29 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2002 | 307 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2003 | 506 | 0.010 |
Why?
|
| Statistical Distributions | 1 | 1999 | 7 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 538 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1999 | 37 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2002 | 471 | 0.010 |
Why?
|
| Intelligence Tests | 1 | 1999 | 55 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 1999 | 44 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 858 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1999 | 50 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2002 | 431 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2000 | 335 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 1999 | 253 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2003 | 728 | 0.010 |
Why?
|
| Models, Genetic | 1 | 1999 | 524 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 4148 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 2067 | 0.010 |
Why?
|
| Cell Line | 1 | 2000 | 2823 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 2883 | 0.010 |
Why?
|
| Genotype | 1 | 1999 | 1852 | 0.010 |
Why?
|
| Sex Factors | 1 | 1999 | 2105 | 0.010 |
Why?
|
| Macrophages | 1 | 2000 | 1507 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1999 | 11853 | 0.000 |
Why?
|
| Child | 1 | 1999 | 22707 | 0.000 |
Why?
|